Upendo L. Mseka

Upendo L. Mseka

Auto-generated profile, based on publicly available information

Upendo L. Mseka

Infection and Immunity Group, Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in eClinicalMedicine
Verified
Journal Article
Open access
UMUpendo L. Mseka
Upendo L. Mseka
JMJonathan Mandolo
Jonathan Mandolo
KNKenneth Nyoni
Kenneth Nyoni
ODOscar Divala
Oscar Divala
DKDzinkambani Kambalame
Dzinkambani Kambalame
ACAnnie Chauma-Mwale
Annie Chauma-Mwale
The B.1.1.529 (Omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the fourth COVID-19 pandemic wave across the southern African region, including Malawi. The seroprevalence of SARS-CoV-2 antibodies and their association with epidemiological trends of hospitalisations and deaths are needed to aid locally relevant public health policy decisions. We conducted a population-based serosurvey from December 27, 2021 to January 17, 2022, in 7 districts across Malawi to determine the seroprevalence of SARS-CoV-2 antibodies. Serum samples were tested for antibodies against SARS-CoV-2 receptor binding domain using WANTAI SARS-CoV-2 Receptor Binding Domain total antibody commercial enzyme-linked immunosorbent assay (ELISA). We also evaluated COVID-19 epidemiologic trends in Malawi, including cases, hospitalisations and deaths from April 1, 2021 through April 30, 2022, collected using the routine national COVID-19 reporting system. A multivariable logistic regression model was developed to investigate the factors associated with SARS-CoV-2 seropositivity. Serum samples were analysed from 4619 participants (57% female; 60% aged 18-50 years), of whom 878/3794 (23%) of vaccine eligible adults had received a single dose of any COVID-19 vaccine. The overall assay-adjusted seroprevalence was 83.7% (95% confidence interval (CI), 79.3%-93.4%). Seroprevalence was lowest among children <13 years of age (66%) and highest among adults 18-50 years of age (82%). Seroprevalence was higher among vaccinated compared to unvaccinated participants (1 dose, 94% vs. 77%, adjusted odds ratio 4.89 [95% CI, 3.43-7.22]; 2 doses, 97% vs. 77%, aOR 6.62 [95% CI, 4.14-11.3]). Urban residents were more likely to be seropositive than those from rural settings (91% vs. 78%, aOR 2.76 [95% CI, 2.16-3.55]). There was at least a two-fold reduction in the proportion of hospitalisations and deaths among the reported cases in the fourth wave compared to the third wave (hospitalisations, 10.7% (95% CI, 10.2-11.3) vs. 4.86% (95% CI, 4.52-5.23), p < 0.0001; deaths, 3.48% (95% CI, 3.18-3.81) vs. 1.15% (95% CI, 1.00-1.34), p < 0.0001). We report reduction in proportion of hospitalisations and deaths from SARS-CoV-2 infections during the Omicron variant dominated wave in Malawi, in the context of high SARS-CoV-2 seroprevalence and low COVID-19 vaccination coverage. These findings suggest that COVID-19 vaccination policy in high seroprevalence settings may need to be amended from mass campaigns to targeted vaccination of reported at-risk populations. Supported by the Bill and Melinda Gates Foundation (INV-039481).

31 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
LNLatif Ndeketa
Latif Ndeketa
DHDaniel Hungerford
Daniel Hungerford
VPVirginia E. Pitzer
Virginia E. Pitzer
Khuzwayo Chidiwa JereKhuzwayo Chidiwa Jere
Khuzwayo Chidiwa Jere
KJKondwani C. Jambo
Kondwani C. Jambo
PDPeter J. Dodd
Peter J. Dodd
Background: Use of oral cholera vaccine (OCV) is globally recommended as a public health response to cholera outbreaks, alongside water, sanitation and hygiene (WASH) interventions. Estimating vaccine effectiveness during emergencies in low- and middle-income countries is challenging because vaccination campaigns are often implemented over short time frames, while individual-level data are frequently incomplete due to constraints in infrastructure, resources and data systems. There is a need for pragmatic approaches that can generate timely, policy-relevant evidence using routinely collected data. Methods: We analysed routine surveillance data from a large 2022–2023 cholera outbreak in Blantyre District, Malawi. The EpiEstim framework was used to generate estimates of the time-varying reproduction number (Rₜ) from line-listed case data. We modelled changes in 𝑅 ???? as a function of cumulative OCV coverage using a log-linear framework and propagated uncertainty through posterior sampling. Lagged WASH exposure variables were incorporated in the model to generate adjusted vaccine effectiveness estimates and to explore potential interaction effects. Sensitivity analyses assessed robustness to alternative lag structures. Findings: The Blantyre outbreak was characterised by an initial period of low-level transmission followed by a sharp increase in cases from late November 2022, after which transmission declined steadily through April 2023. This decline coincided with the implementation of a reactive OCV campaign. The majority of the cases were among middle-aged men living in urban Blantyre. The unadjusted vaccine-associated reduction in transmission was estimated at 53.52% (95% credible interval (CrI):42.5–64.1%). After adjusting for a 7-day rolling average WASH activity, total vaccine effectiveness increased to 62.1% (95% CrI: 49.3–74.9%). Sensitivity analyses using alternative lag structures for WASH exposure produced comparable adjusted estimates. Interpretation: Implementation of OCV contributed to a substantial reduction in cholera transmission during the outbreak. This study demonstrates a feasible approach for estimating vaccine-attributable impact whilst accounting for public health and social measures, such as WASH interventions. The methods described will be useful in outbreaks where classical observational designs are not possible, providing actionable evidence to policy makers for outbreak response in resource-limited settings. Funding: MRC Discovery Medicine North (DiMeN) Doctoral Training Partnership (UKRI), National Institute for Health and Care Research (NIHR) Global Health Research Group on Gastrointestinal Infections and Wellcome through the core grant to the Malawi-Liverpool-Wellcome Research Programme. Research in context: Evidence before this study: Before undertaking this analysis, our team and collaborators generated detailed epidemiological and genomic evidence describing the 2022–2023 cholera outbreak in Blantyre, Malawi. Our previous fine-scale spatial work demonstrated marked heterogeneity in cholera burden across urban Blantyre. We found that transmission concentrated in densely populated informal settlements and areas with poor water and sanitation infrastructure. Our genomic analysis of outbreak isolates showed that the epidemic was driven by a recently introduced seventh-pandemic El Tor Vibrio cholerae sub-lineage AFR15 linked to regional and international transmission events, with epidemic expansion occurring during late 2022. These studies characterised where transmission occurred and the evolutionary origin of the outbreak strain. The population-level effect of reactive oral cholera vaccination (OCV) or concurrent and improved water, sanitation and hygiene (WASH) interventions on transmission dynamics during the outbreak was not quantified. In linked work, we conducted a systematic review of post-licensure vaccine impact and effectiveness studies from sub-Saharan Africa (CRD42023436851) to assess the principal study designs and the extent to which they adjusted for concurrent public health and social measures (PHSMs), such as WASH interventions. We searched PubMed, EMBASE, MEDLINE, CINAHL, and Google Scholar for vaccine impact or effectiveness studies conducted in children under five years and screened reference lists of included studies. Across all eligible studies, none measured or adjusted for concurrent PHSMs. Added value of this study: Using surveillance, vaccination, and WASH data collected from Blantyre district by the Malawi Ministry of Health, we estimated the vaccine-associated reduction in transmission during a large reactive OCV campaign. By linking time-varying R ₜ estimates to cumulative vaccine coverage within a posterior sampling framework, we provide field-relevant effectiveness estimates from a setting where traditional individual-level designs were not feasible. We further evaluated whether concurrent WASH activity materially altered vaccine effect estimates. Implications of all the available evidence: Taken together with prior spatial and genomic analyses of the same outbreak, our findings provide a more complete picture of cholera control in Malawi. The earlier work clarified transmission geography and pathogen introduction. The present analysis quantifies the population-level impact of reactive vaccination under real-world programme conditions. This integrated evidence base supports ministries of health in interpreting vaccine performance during rapidly evolving outbreaks and in strengthening the routine data systems required for timely evaluation of interventions.